 | This article needs to beupdated. Please help update this article to reflect recent events or newly available information.(October 2021) |
 Share of population in Kazakhstan that has received at least one dose ofCOVID-19 vaccine by region as of 29 July 2022 | |
| Date | 1 February 2021 (2021-02-01) – present |
|---|---|
| Location | Kazakhstan |
| Cause | COVID-19 pandemic in Kazakhstan |
| Part ofa series on the |
| COVID-19 pandemic |
|---|
 |
|
Medical response |
|
.svg) COVID-19 portal |
COVID-19 vaccination in Kazakhstan is an ongoingimmunization campaign againstsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causescoronavirus disease 2019 (COVID-19), in response to theongoing pandemic in the country.[citation needed]
Shortly after theCOVID-19 outbreak in Kazakhstan, Erlan Ramanqūlov, the Director General of the National Center for Biotechnology announced in April 2020 the stages on developing the COVID-19 vaccine, acknowledging that clinical trials usually take up to 10 years to develop and that all verified research process would be cut short due to the intense situation in the country, expediting the coronavirus vaccine production and forecasted that it would be available to the public within the next year and a half.[1]
On 18 May 2020, theMinistry of Education and Science announced that the preclinical trials for the local COVID-19 vaccine had begun of which was developed by the employees of the Research Institute of Biological Safety Problems of the Science Committee (BQPĞZÏ) under the Ministry by the strain of the coronavirus isolated from patients and that theWorld Health Organization (WHO) had registered the vaccine development.[2] At the cabinet meeting, Education and Science MinisterAshat Aimagambetov announced that five COVID-19 vaccines were being developed and that the preclinical trials would be tested on animals until September 2020, when the clinical stages would begin for humans.[3] In August 2020, the National Center for Expertise of Medicines and Medical Devices reported that theQazCovid-in vaccine showed no dangers during preclinical study stage and ruled that the testing could advance further into clinical trials on humans.[4] Starting 1 September 2020, the BQPĞZI began recruiting volunteers for conducting clinical trials of QazCovid-in.[5] In December 2020, theMinistry of Healthcare approved the final phase III of clinical trials by the BQPĞZI for 3,000 volunteers, by which the institute reported 96% efficiency rate of QazCovid-in.[6]
Kazakhstan has created its own COVID-19 vaccination, QazCovid-in, developed by the Research Institute for Biological Safety Problems.[7] On 7 April 2021, the Healthcare MinisterAlexey Tsoi announced that the Kazakh government had requested 4 million doses of Russia'sSputnik V vaccine, in addition to 2 million doses already received earlier in 2021, as part of an ongoing vaccination programme alongside QazCovid-in.[8]
In October 2021, the first Kazakh vaccine to protect cats from COVID-19, NARUVAX-C19, was unveiled at the Kazagro/Kazfarm-2021 international exhibition.[9]
| Vaccine | Approval | Deployment |
|---|---|---|
| Sputnik V |  Yes | Yes |
| QazCovid-in | Yes | Yes |
| Sinopharm BIBP[10] | Yes | Yes |
| Sinovac[11] | Yes | Yes |
| Sputnik Light[12] | Yes |  No |
| QazCoVac-P | No | No |
| Region | Vaccinated population (as of 29 July 2022)[13] | |||||
|---|---|---|---|---|---|---|
| Amount | Percentage | |||||
| 1st dose | 2nd dose | Booster dose | 1st dose | 2nd dose | Booster dose | |
| Akmola Region | 376,526 | 363,785 | 51.3% | 49.6% | ||
| Aktobe Region | 442,646 | 435,541 | 48.6% | 47.8% | ||
| Almaty Region | 1,183,805 | 1,130,834 | 55.9% | 53.4% | ||
| Atyrau Region | 292,152 | 276,467 | 43.4% | 41.1% | ||
| East Kazakhstan Region | 1,032,215 | 1,025,710 | 76.2% | 75.7% | ||
| Jambyl Region | 772,156 | 762,453 | 67.0% | 66.1% | ||
| Karaganda Region | 726,370 | 678,609 | 53.0% | 49.5% | ||
| Kostanay Region | 380,772 | 367,483 | 44.5% | 42.9% | ||
| Kyzylorda Region | 516,071 | 510,599 | 62.0% | 61.4% | ||
| Mangystau Region | 279,861 | 272,261 | 37.3% | 36.3% | ||
| Pavlodar Region | 385,060 | 375,954 | 51.6% | 50.4% | ||
| North Kazakhstan Region | 342,656 | 338,133 | 64.1% | 63.3% | ||
| Turkistan Region | 1,294,982 | 1,290,145 | 62.0% | 61.8% | ||
| West Kazakhstan Region | 297,268 | 287,561 | 44.5% | 43.1% | ||
| Almaty | 1,211,479 | 1,186,646 | 59.1% | 57.9% | ||
| Nur-Sultan | 542,653 | 516,130 | 43.0% | 40.9% | ||
| Shymkent | 707,126 | 696,298 | 62.9% | 61.9% | ||
 Kazakhstan | 10,783,798 | 10,514,609 | 5,012,630 | 57.5% | 56.1% | 26.7% |
| Total doses: | 26,311,037 | |||||
